Effects of Intravenous GC4419 on the Incidence and Severity of Esophagitis Due to Chemoradiotherapy for Lung Cancer
Status:
Recruiting
Trial end date:
2021-12-01
Target enrollment:
Participant gender:
Summary
GTI-4419-203 will be an open-label, multi-center study to evaluate GC4419 administered
intravenous (IV) for the reduction of radiation induced esophagitis in subjects receiving
chemoradiotherapy for unresectable Stage 3A/3B or post-operative Stage 2B NSCLC, SCLC
treatable with chemoradiotherapy.